Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0UHEOR)
| ADC Name |
Mocertatug rezetecan
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
mocertatug rezetecan; HS-20089; GSK5733584; GSK'584; mo-rez
Click to Show/Hide
|
|||||
| Organization |
Hansoh Pharmaceutical (Originator);GSK (Top20 MNC)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Mocertatug
|
Antibody Info | ||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
SHR9265
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
rezetecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
2 Trials
|
||||||||||
| Peritoneal cancer |
1 Trials
|
2 Trials
|
|||||||||
| Ovarian cancer |
1 Trials
|
1 Trials
|
2 Trials
|
||||||||
| Fallopian tube cancer |
1 Trials
|
2 Trials
|
|||||||||
| Endometrial cancer |
1 Trials
|
1 Trials
|
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease control rate (DCR) |
63.60%
|
|||
| Patients Enrolled |
Key inclusion: Adults ≥18 with histologically/cytologically confirmed advanced solid tumors (≥1 RECIST 1.1 measurable lesion: ≥10mm for non-nodal/≥15mm for nodal lesions), ECOG 0-1, life expectancy >12 weeks, contraception compliance, and signed informed consent. Standard treatment must be ineffective/unavailable/intolerable.
|
||||
| Administration Dosage |
HS-20089 for IV infusion of various dose strengths administered in 21 day dosing cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05263479 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20089 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoint is MTD determination of HS-20089 in advanced solid tumor patients within 3 weeks of treatment initiation, with safety monitoring through CTCAE criteria until 90 days post-last dose.
|
||||
| Other Endpoint |
Secondary endpoints include PK profiling (Cmax/t1/2/AUC0-24/AUC0-t/AUC0-∞ post-single dose; Cmax ss in 21-day cycles), immunogenicity (ADA development), and efficacy evaluation (confirmed ORR per RECIST 1.1 with ≥4-week validation, tracked up to 2 years).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Key inclusion: Adults ≥18 with recurrent/metastatic solid tumors (ovarian/endometrial focus), ≥1 measurable lesion (non-CNS/bone-only), mandatory tumor tissue, ECOG 0-1, ≥12-week life expectancy, contraception until 6mo post-treatment, and protocol compliance.
|
||||
| Administration Dosage |
Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg; Patients in cohort 2/3/4 of phase 2a will receive HS-20089 at 5.8 mg/kg; Patients of phase 2b will receive HS-20089 at recommended dose..
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06014190 | Clinical Status | PHASE2 | ||
| Clinical Description | A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer | ||||
| Primary Endpoint |
Primary endpoints include investigator-assessed ORR per RECIST 1.1 (confirmed CR/PR) and GCIG CA-125 criteria for ovarian cancer, with safety monitoring of AEs (CTCAE v5.0) until 90 days post-treatment.
|
||||
| Other Endpoint |
Secondary endpoints cover IRC-confirmed efficacy (ORR/DCR/DoR/PFS/OS), PK parameters (Cmax/Tmax/AUC), ADA development, and ovarian cancer-specific CA-125 response in evaluable patients (baseline ≥2×ULN).
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Key inclusion: Women ≥18 with platinum-resistant epithelial ovarian/primary peritoneal/fallopian tube cancer, ≥1 measurable lesion (RECIST 1.1), ECOG 0-1, life expectancy >12 weeks, tumor tissue availability, adequate organ function, and contraception compliance.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06855069 | Clinical Status | PHASE3 | ||
| Clinical Description | A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | ||||
| Primary Endpoint |
Primary endpoint is BIRC-assessed PFS per RECIST 1.1 from screening to study completion (average 1 year).
|
||||
| Other Endpoint |
Secondary endpoints include OS, investigator/BIRC-assessed ORR/DoR/DCR per RECIST 1.1, and AE monitoring, all evaluated from screening to study completion (average 1 year).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Key inclusion: Adults ≥18 with advanced solid tumors (RECIST 1.1 measurable lesions), ECOG 0-1, life expectancy ≥12 weeks, contraception compliance, negative pregnancy test (HCG-confirmed if needed), and voluntary informed consent.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06769425 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects with Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include MTD/MAD determination in dose escalation (Cycle 1, 21 days) and ORR assessment in dose expansion (RECIST v1.1/PCWG3 for prostate cancer, RECIST v1.1+GCIG CA-125 for ovarian cancer) over 2 years.
|
||||
| Other Endpoint |
Secondary endpoints cover safety (CTCAE v5.0), PK parameters (Cmax/Tmax/AUC0-t in Cycle 1; Css,max/Tss,max/Css,min/AUCss in Cycle 2), and efficacy measures (DCR/DoR/PFS/rPFS/OS over 2-4 years) with tumor-specific assessments (CA-50% reduction for ovarian cancer, PSA50/time-to-PSA-progression for prostate cancer).
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Key inclusion: Adults ≥18 with histologically-confirmed advanced solid tumors (≥1 RECIST 1.1 measurable non-CNS/bone lesion), mandatory tumor tissue submission, ECOG 0-1, life expectancy ≥12 weeks, contraception compliance, negative pregnancy test (HCG-confirmed if needed), and voluntary informed consent.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06336707 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary objective is to determine MTD/MAD of HS-20089 combination therapy within 21 days of first dose, with safety monitoring via CTCAE v5.0 until 90 days post-treatment.
|
||||
| Other Endpoint |
Secondary objectives include PK analysis (Cmax/Tmax/AUC0-t/AUC0-∞ in Cycle 1), immunogenicity (ADA detection), and efficacy evaluation (investigator-assessed ORR/DCR/DoR/PFS per RECIST 1.1 and OS, all tracked up to 24 months).
|
||||
| Experiment 6 Reporting the Activity Date of This ADC | [6] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05263479 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HS-20089 in patients with advanced solid tumors. | ||||
References